We previously observed that pulmonary hypertension secondary to myocardial infarction (MI) in swine is characterized by elevated plasma endothelin (ET) levels and pulmonary vascular resistance (PVR). Consequently, we tested the hypothesis that an increased ET-mediated vasoconstrictor influence contributes to secondary pulmonary hypertension after MI and investigated the involvement of ET A and ET B receptor subtypes. Chronically instrumented swine with (MI swine; n = 25) or without (normal swine; n = 19) MI were studied at rest and during treadmill exercise (up to 4 km h -1 ), in the absence and presence of the ET A antagonist EMD 122946 or the mixed ET A /ET B antagonist tezosentan. In normal swine, exercise caused a small decrease in PVR. ET A blockade had no effect on PVR at rest or during exercise. Conversely, ET A /ET B blockade decreased PVR but only during exercise (at 4 km h -1 , from 3.0 ± 0.1 to 2.3 ± 0.1 mmHg min l -1 ; P ≤ 0.05). MI increased pulmonary arterial pressure and PVR both at rest and during exercise (both P ≤ 0.05). The increased pulmonary arterial pressure correlated with the increased plasma ET levels in resting MI swine (r = 0.71; P ≤ 0.01). Furthermore, the pulmonary vasoconstrictor response to ET-1 infusion was enhanced after MI (P ≤ 0.05). ET A /ET B blockade decreased PVR in MI swine from 3.6 ± 0.3 to 3.1 ± 0.5 mmHg min l -1 at rest and from 3.4 ± 0.3 to 2.4 ± 0.2 mmHg min l -1 during exercise at 4 km h -1 (both P ≤ 0.05). This increased response to mixed ET A /ET B blockade in MI compared to normal swine appeared to be the result of an increased ET A -mediated vasoconstriction, as ET A blockade decreased PVR in MI swine from 3.4 ± 0.4 to 2.8 ± 0.2 mmHg min l -1 at rest and from 3.1 ± 0.3 to 2.6 ± 0.2 mmHg min l -1 at 4 km h -1 (both P ≤ 0.05). In conclusion, increased plasma ET levels together with increased pulmonary resistance vessel responsiveness to ET result in an exaggerated pulmonary vasoconstrictor influence of ET in swine with a recent MI. This vasoconstrictor influence is the result of an emergent tonic ET A -mediated vasoconstriction in addition to the exercise-induced ET B -mediated vasoconstriction that is already present in normal swine. Congestive heart failure is the only major cardiovascular disorder of which the incidence has increased over the past decade, and this is principally due to a reduction in mortality associated with acute myocardial infarction (MI) (Colucci & Braunwald, 2001 ). The loss of viable myocardial tissue after MI causes left ventricular dysfunction leading to an increase in left ventricular filling pressure and neurohumoral activation particularly during exercise (Colucci & Braunwald, 2001; Haitsma et al. 2001; van der Velden et al. 2004; Merkus et al. 2005) . The increase in left ventricular filling pressure is transmitted backwards into the pulmonary circulation, resulting in pulmonary congestion and an increase in pulmonary arterial blood pressure, thereby elevating right ventricular afterload (van Kats et al. 2000; Haitsma et al. 2001) . The resultant right ventricular hypertrophy is a risk factor for the development of right-sided heart failure (Guarracino et al. 2005) .
Congestive heart failure is the only major cardiovascular disorder of which the incidence has increased over the past decade, and this is principally due to a reduction in mortality associated with acute myocardial infarction (MI) (Colucci & Braunwald, 2001 ). The loss of viable myocardial tissue after MI causes left ventricular dysfunction leading to an increase in left ventricular filling pressure and neurohumoral activation particularly during exercise (Colucci & Braunwald, 2001; Haitsma et al. 2001; van der Velden et al. 2004; Merkus et al. 2005) . The increase in left ventricular filling pressure is transmitted backwards into the pulmonary circulation, resulting in pulmonary congestion and an increase in pulmonary arterial blood pressure, thereby elevating right ventricular afterload (van Kats et al. 2000; Haitsma et al. 2001) . The resultant right ventricular hypertrophy is a risk factor for the development of right-sided heart failure (Guarracino et al. 2005) .
In addition to the backwards transmission of left atrial pressure into the pulmonary circulation, an elevated pulmonary vascular resistance (PVR), associated with activation of the endothelin (ET) system, also contributes to pulmonary hypertension secondary to MI (Remetz et al. 1989; Haitsma et al. 2001; Nauser & Stites, 2001) . ET-1 is one of the most potent vasoconstrictors known to date and is produced in endothelial cells. Its role in pulmonary hypertension is supported by increased levels of circulating ET, as well as increased local production (Dupuis et al. 1996; Sakai et al. 1996; Moraes et al. 2000) . Moreover, there is a correlation between ET plasma levels and the severity of pulmonary hypertension in patients with chronic heart failure (Cody et al. 1992) .
Both ET A and ET B receptors have been identified in the pulmonary vasculature (MacLean et al. 1994; Soma et al. 1999) . ET A and ET B receptors on vascular smooth muscle induce vasoconstriction, whereas ET B receptors on the endothelium induce vasodilatation through production of NO and prostacyclin. We have previously shown, that endogenous ET-mediated pulmonary vasoconstriction in normal swine occurs predominantly through the ET B receptors (Merkus et al. 2003) , indicating that the vasoconstrictor effect of ET B receptors on vascular smooth muscle is larger than the vasodilator effect of ET B receptors on the endothelium, while ET A receptors have virtually no influence on the pulmonary circulation. The endothelial ET B receptors are also responsible for the plasma clearance of ET in the lungs (Fukuroda et al. 1994) , which is reduced in relation to the severity of pulmonary hypertension in patients with chronic heart failure (Staniloae et al. 2004) . The reduced pulmonary clearance of ET and the increased plasma ET levels after MI suggest that ET can contribute to the aggravation of pulmonary hypertension. Indeed, studies in patients with pulmonary hypertension secondary to MI suggest that ET A as well as ET A /ET B receptor blockade are capable of improving clinical conditions (Motte et al. 2005) . However, to date no study has addressed the effect of ET receptor antagonists on PVR after MI.
The aim of the present study was therefore to test the hypothesis that an increased ET-mediated vasoconstrictor influence in the pulmonary circulation contributes to secondary pulmonary hypertension in swine with a recent MI (MI swine). For this purpose, we first investigated in awake resting swine; whether plasma ET levels and pulmonary vascular responsiveness to exogenous ET are increased after MI. Subsequently, we investigated whether the vasoconstrictor influence of endogenous ET was increased in the pulmonary circulation and assessed the role of ET A and ET B receptor subtypes in this process. Because in normal swine a pulmonary ET-mediated vasoconstrictor influence emerges during exercise, but is negligible under resting conditions (Merkus et al. 2003) , the vasoconstrictor influence of endogenous ET in MI swine was studied both at rest and during treadmill exercise.
Methods

Animals
Studies were performed in accordance with the Council of Europe Convention (ETS123)/Directive (86/609/EEC) for the protection of vertebrate animals used for experimental and other scientific purposes, and with approval of the Animal Care Committee at Erasmus MC, University Medical Centre Rotterdam. A total of 47 Yorkshire × Landrace swine (2-3 months old, 22 ± 1 kg at the time of surgery) of either sex entered the study. After completing all experimental protocols, animals were killed by an intravenous overdose of pentobarbitone sodium.
Surgery
Swine were sedated with ketamine (30 mg kg −1 i.m.), anaesthetized with thiopental (10 mg kg −1 i.v.), intubated and ventilated with a mixture of O 2 and N 2 O (1 : 2) to which 0.2-1% (v/v) isoflurane was added (Stubenitsky et al. 1998; Duncker et al. 2001) . Anaesthesia was maintained with midazolam (2 mg kg −1 + 1 mg kg
i.v.) and fentanyl (10 μg kg
. Under sterile conditions, the chest was opened via the fourth left intercostal space and a fluid-filled polyvinylchloride catheter was inserted into the aortic arch and pulmonary artery for blood pressure measurement (Combitrans pressure transducers, Braun, Melsungen, Germany) and blood sampling. An electromagnetic flow probe (14-15 mm, Skalar) was positioned around the ascending aorta for measurement of cardiac output. A polyvinylchloride catheter was also inserted into the left atrium to measure pressure. In all 47 swine, the proximal part of the left coronary circumflex artery (LCx) was exposed, but the LCx was permanently occluded with a silk suture to produce an MI in only 22 of the animals (Haitsma et al. 2001; van der Velden et al. 2004) . Three MI swine died during surgery due to recurrent fibrillation. Catheters were tunnelled to the back and animals were allowed to recover, receiving analgesia (0.3 mg buprenorphine i.m.) for 2 days and antibiotic prophylaxis (25 mg kg −1 amoxicillin and 5 mg kg −1 gentamycin i.v.) for 5 days.
Resting protocols
Experimental design. Resting studies were performed 17 ± 1 days after surgery with animals resting quietly on the treadmill. A total number of 19 normal and 18 MI swine were used in the resting protocols. In the first resting protocol we evaluated the effects of MI on resting haemodynamic variables and plasma ET levels. In the second resting protocol we evaluated the pulmonary resistance vessel responses to ET by intravenously infusing exogenous ET-1.
Pulmonary arterial pressure and plasma levels of ET.
Plasma levels of ET were determined in 15 normal and 18 MI swine. As we have recently shown that exercise does not affect plasma levels of ET in either normal or MI swine , we elected to determine plasma ET levels only under resting conditions. Arterial blood samples (5 ml) in all swine were collected in tubes containing EDTA. Samples were centrifuged (3000g; 10 min; 4 • C) and plasma was stored at −80 • C. Plasma levels of ET-like immunoreactivity were determined using a radioimmuno assay from Euro-Diagnostica (Malmö, Sweden), which has a cross reactivity of 100% towards ET-1, 48% towards ET-2 and 109% towards ET-3 (Merkus et al. 2003) . Because production of ET-2 and ET-3 appears to be absent in the cardiovascular system of the swine (Kjekshus et al. 2000) , the concentrations measured with the radioimmuno assay most probably represent ET-1. Resting haemodynamic measurements consisting of aortic, left atrial and pulmonary arterial blood pressures and cardiac output were obtained.
Exogenous ET-1 infusions. With swine (n = 6 normal and n = 3 MI) resting quietly, resting haemodynamic measurements were obtained. Subsequently, ET-1 was infused i.v. via the pulmonary arterial catheter at rates of 20 and 40 pmol kg −1 min −1 and resting haemodynamic measurements were again obtained at the end of each 10-min infusion period.
Exercise protocols
Experimental design.
Studies were performed 11 ± 1 days after surgery with animals exercising on a motor-driven treadmill. The two exercise protocols were performed on different days and in random order. A total number of 14 normal and nine MI swine were used in the exercise protocols, of which eight normal and eight MI swine were also used in the resting protocols. In the first exercise protocol, we evaluated the vasoconstrictor influence of endogenous ET, using a mixed ET A /ET B receptor antagonist. In the second protocol, we assessed the role of the ET A receptor subtype in the vasoconstrictor influence of endogenous ET in MI swine, using a selective ET A receptor antagonist. We refrained from studying the effects of a selective ET B receptor antagonist, because the ET B receptor is responsible for clearance of ET in the lungs (Fukuroda et al. 1994; Merkus et al. 2003) . Hence, ET B blockade increases ET levels, which can then act through the ET A receptor to cause vasoconstriction, thereby confounding interpretation of the results. Consequently, the contribution of the ET B receptor must be derived from the difference in response to the ET A and the ET A /ET B receptor antagonists.
Effects of combined ET A and ET B receptor blockade.
With swine (n = 13 normal and n = 9 MI) lying quietly on the treadmill, resting haemodynamic measurements consisting of left atrial, aortic and pulmonary arterial blood pressures and cardiac output were obtained and arterial and mixed venous blood samples were collected. Haemodynamic measurements were repeated and rectal temperature measured with animals standing on the treadmill. Subsequently, a four-stage exercise protocol (1, 2, 3 and 4 km h −1 ) was begun with each stage lasting 2-3 min. Haemodynamic variables were measured and blood samples collected during the last 30 s of each exercise stage, when haemodynamic variables had reached a steady state. At the conclusion of the exercise protocol, animals were allowed to rest for 90 min. Then, animals received the mixed ET A and ET B receptor antagonist tezosentan (a gift from Dr Clozel, Actelion Pharmaceuticals Ltd, Allschwill, Switzerland) intravenously over 10 min at a dose of 3 mg kg −1 , followed by a continuous infusion of 6 mg kg Merkus et al. 2003) , and the exercise protocol was repeated. Tezosentan has a pA 2 of 9.5 for ET A and a pA 2 of 7.7 for ET B receptors, indicating only a 63-fold selectivity for ET A compared to ET B receptors (Clozel et al. 1999) . Moreover, we have previously shown that the employed dose of tezosentan blocks the pressor response to intravenous ET infusion and results in an increase in plasma ET levels, indicating that both ET A and ET B receptors are blocked (Merkus et al. 2003) .
Effects of ET A receptor blockade. Swine (n = 9 normal and n = 8 MI) received the ET A receptor antagonist EMD 122946 (a gift from Professor Schelling, E. Merck Darmstadt, Darmstadt, Germany) at a dose of 3 mg kg −1 intravenously, 90 min after they underwent the exercise protocol under control conditions (Merkus et al. 2003) . EMD 122946 has a pA 2 of 9.5 for ET A and a pA 2 of 6.0 for ET B receptors, indicating a 3200-fold selectivity for ET A compared to ET B receptors (Mederski et al. 1998) . EMD 122946 in a dose of 3 mg kg −1 blocks the pressor response to intravenously infused ET. In contrast, this dose of EMD 122946 does not block ET B receptors, as ET B -mediated clearance of ET is not affected by administration of EMD 122946 as demonstrated by unaltered ET plasma levels (Merkus et al. 2003) . Resting measurements were obtained and the exercise protocol repeated 5 min after completion of the infusion.
Blood gas measurements
Blood samples obtained in the exercise protocols, were kept in syringes on-ice until the conclusion of each exercise trial. Measurements of P O 2 (mmHg), P CO 2 (mmHg) and pH were then immediately performed with a blood gas analyser (Acid-Base Laboratory Model 505, Radiometer, Copenhagen, Denmark). Oxygen saturation (%) and haemoglobin level (g dl −1 ) were measured with a haemoximeter (OSM3, Radiometer). Blood O 2 J Physiol 574.2 content (μmol ml −1 ) was computed as (Hb × 0.621 × O 2 saturation) + (0.00131 × P O 2 ). Body O 2 consumption (BV O 2 ) was calculated as the product of cardiac output and the difference in O 2 content between arterial and mixed venous blood (Stubenitsky et al. 1998; Duncker et al. 2001) .
Data analysis
Digital recording and off-line analysis of haemodynamic variables have been described in detail elsewhere (Stubenitsky et al. 1998; Duncker et al. 2001) . Systemic vascular resistance was computed as mean aortic blood pressure divided by cardiac output. PVR was computed as mean pulmonary arterial pressure minus mean left atrial pressure divided by cardiac output.
Statistical analysis
The effect of MI on pulmonary arterial pressure and plasma ET levels was assessed using an unpaired t test. The relation between endogenous ET and pulmonary arterial pressure was assessed using linear regression, whereas statistical analysis of the effect of exogenous ET on systemic vascular resistance and PVR in normal versus MI swine was performed using analysis of variances (ANOVA). To test for the effects of MI and drug treatment (EMD 122946 or tezosentan) on the relation between BV O 2 and systemic vascular resistance or PVR, regression analysis was performed using MI, drug treatment and BV O 2 , as well as their interaction, as independent variables and assigning a dummy variable to each animal. Statistical significance was accepted when P ≤ 0.05. Data are presented as mean ± s.e.m. . Inclusion of both MI and normal swine resulted in a highly similar correlation between pulmonary arterial pressure (PAP) and ET plasma levels (PAP = 4.9 × ET + 3.5, r = 0.703), as compared to inclusion of MI swine alone (PAP = 5.2 × ET + 3.6; r = 0.708). * P ≤ 0.05 MI versus normal swine.
Results
ET and MI at rest
After MI, mean resting pulmonary arterial pressure increased from 15 ± 1 to 24 ± 3 mmHg (Fig. 1A) , which was in part the result of the increased mean left atrial pressure (normal swine, 4 ± 1 mmHg; MI swine, 12 ± 2 mmHg). Resting ET plasma levels were elevated in MI (3.8 ± 0.4 pmol l −1 ) compared to normal swine (2.7 ± 0.3 pmol l −1 , P ≤ 0.05) (Fig. 1B) . Furthermore, a significant correlation existed between pulmonary arterial pressure and ET levels in MI swine (r = 0.708; P ≤ 0.01) (Fig. 1C) , supporting a role for ET in pulmonary hypertension after MI.
To investigate whether the responsiveness to ET is changed after MI, different doses of ET-1 were infused. In the systemic circulation, ET-1 infusion resulted in a progressive increase in the vascular resistance that was similar in both normal and MI swine (Fig. 2) . In contrast, whereas ET-1 at a dose of 20 pmol kg −1 min −1 induced no significant change in PVR in either group of swine, at 40 pmol kg −1 min −1 ET-1 produced a significantly greater increase in PVR in MI compared to normal swine (Fig. 2) .
Changes in haemodynamic variables after MI at rest and exercise
Exercise up to 4 km h −1 in normal swine resulted in a tripling of BV O 2 which was met by a doubling of cardiac output and a ∼40% increase in O 2 extraction (Fig. 3) . The increase in cardiac output was principally due to an increase in heart rate, as stroke volume increased by only 7%. Mean aortic blood pressure was minimally affected ( Table 1 ), implying that the increase in cardiac output was balanced by a similar decrease in systemic vascular resistance. Mean pulmonary arterial pressure almost doubled in normal swine during exercise (Fig. 3) . However, the transpulmonary pressure gradient (pulmonary arterial pressure minus left atrial pressure) increased slightly less than cardiac output, reflecting a small decrease in PVR during exercise.
Despite a 17% lower stroke volume in MI compared to normal swine, cardiac output was virtually maintained both at rest and during treadmill exercise, which was the result of a higher heart rate (Fig. 3) . The slightly lower cardiac output during exercise necessitated a small increase in O 2 extraction, resulting in a decrease in mixed venous O 2 saturation. Pulmonary arterial pressure was elevated, which was due to a marked increase in left atrial pressure but also due to ∼15% increase in PVR (Fig. 3) The role of ET in the regulation of vascular tone
In normal swine, ET A /ET B receptor blockade with tezosentan had no effect on the pulmonary circulation under resting conditions (Table 1 and Fig. 4 
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.3 ± 0.3 -13.1 ± 0.6 * 15.3 ± 0.7 * 17.6 ± 0.7 * 21.8 ± 0.7 * Tezosentan − 7.7 ± 0.3 -13.5 ± 0.7 * 15.3 ± 0.6 * 18.3 ± 0.8 * 22.5 ± 0.9 * Control + 6.8 ± 0.5 -13.0 ± 0.8 * 14.6 ± 0.9 * 17.5 ± 1.3 * 21.2 ± 1.2 * Tezosentan + 6.4 ± 0.4 ‡ -13.6 ± 0.7 * 15.5 ± 0.8 * 17.9 ± 1. exercise, however, tezosentan reduced pulmonary arterial pressure with no effect on left atrial pressure and caused a small increase in cardiac output (Table 1) , implying a decrease in PVR. The tezosentan-induced decrease in PVR increased progressively with incremental exercise intensity (Fig. 4) . In contrast, the ET A receptor antagonist EMD 122946 had no effect on pulmonary arterial or left atrial pressure in normal animals either at rest or during exercise ( Table 2 ), so that PVR remained unchanged (Fig. 4) . Hence in normal swine, the vasoconstrictor influence of ET on the pulmonary circulation during exercise is mediated by ET B receptors. In MI swine, ET A /ET B receptor blockade caused a significant decrease in PVR at rest and during exercise (Fig. 4) . ET A receptor blockade also resulted in vasodilatation, demonstrated by a modest decrease in PVR at rest, which was maintained during exercise. The difference between the effect of ET A /ET B blockade and of ET A blockade alone (representing the ET B component) was unchanged in MI compared to normal swine (Fig. 4) . Thus, the increased pulmonary vasoconstrictor influence by endogenous ET in MI swine is principally mediated by ET A receptors.
Administration of the ET A /ET B receptor antagonist tezosentan to normal swine resulted in a decrease in systemic vascular resistance, reflecting vasodilatation in the systemic vasculature at rest and during exercise. There were no differences between the response to tezosentan and EMD 122946 in the systemic circulation of normal swine (Tables 1 and 2 to in normal swine. These findings indicate that the ET-dependent vasoconstrictor influence in the systemic circulation is principally mediated by ET A and is not increased after MI.
Discussion
The main findings of the present study in awake swine with pulmonary hypertension secondary to MI are that: (i) circulating plasma levels of ET as well as the pulmonary vascular responsiveness to exogenous ET-1 are increased; (ii) the increase in ET-mediated vasoconstrictor influence after MI is principally mediated by the ET A receptor; (iii) the pulmonary vasoconstrictor influence of ET that is mediated through the ET B receptor is not altered as compared to in normal swine; (iv) the vasoconstrictor influence of endogenous ET in the systemic circulation did not change after MI. As the role of ET in the systemic circulation, which has been discussed extensively in one of our previous papers (Merkus et al. 2003) , was not altered after MI, we will focus on the pulmonary circulation.
In agreement with previous studies from our laboratory (van Kats et al. 2000; Haitsma et al. 2001 Haitsma et al. , 2002 , MI swine (2 weeks after an MI) have left ventricular (LV) dysfunction, characterized by a lower stroke volume and increased left atrial pressure. The accompanying increase in heart rate resulted in an essentially maintained cardiac output, indicating that overt congestive heart failure is absent (van Kats et al. 2000) . In agreement with clinical observations (Cody et al. 1992) , and with previous observations from our own laboratory (van Kats Haitsma et al. 2001 Haitsma et al. , 2002 , MI swine were characterized by increases in pulmonary arterial pressure and PVR. Furthermore, similar to clinical observations (Cody et al. 1992) , we also found that the severity of pulmonary hypertension and the increase in plasma levels of ET were highly correlated. Moreover, the range of plasma ET levels after MI, which demonstrate increases of up to 4-fold as compared to normal swine, is similar to that found in patients with pulmonary hypertension secondary to MI (Cody et al. 1992 ). These observations indicate that our porcine model recapitulates several aspects of secondary pulmonary hypertension observed in patients after MI.
Elevation of plasma ET levels in pulmonary hypertension
In agreement with previous studies from our laboratory (Haitsma et al. 2001; Merkus et al. 2005) , circulating levels of ET were increased after MI. These elevated ET levels could have been the result of decreased ET clearance, increased ET production, or both.
ET clearance. The pulmonary circulation, together with the kidneys and the liver, is the predominant site in the body for clearance of ET, with single-pass clearance reaching values of up to 30-50% (Dupuis et al. 1994 (Dupuis et al. , 1996 . This clearance is mediated through binding of ET to the ET B receptor on the pulmonary endothelium (Fukuroda et al. 1994) . In the pulmonary circulation of healthy individuals the ET-production and clearance are balanced, such that there is no net difference between pulmonary arterial and venous ET plasma levels (Dupuis et al. 1994 (Dupuis et al. , 1996 . In secondary pulmonary hypertension, increased plasma ET levels can be the result of decreased clearance of ET in the lungs. Indeed, in both experimental models and humans with heart failure, clearance of ET was shown to be reduced (Dupuis et al. 1998a,b; Staniloae et al. 2004) , although this was not a unanimous finding (von Lueder et al. 2004) .
ET production. ET is produced from big-ET by endothelin-converting enzyme (ECE)-1, while big-ET is produced from preproendothelin by furin-like enzymes (Galie et al. 2004) . Hence, increases in either ECE activity or in preproendothelin levels could have contributed to an increase in ET production. The rate-limiting step in the production of ET is thought to be the conversion from big-ET to ET by ECE-1. Increased ET production in pigs with pacing-induced heart failure was attributed to an increased ECE-1 activity (von Lueder et al. 2004 ). The ECE-1 isoform that is involved is still incompletely understood, but is most likely to be the ECE-1a isoform, as ECE-1a mRNA is up-regulated while ECE-1c mRNA appears to remain unaltered (Ergul et al. 2001) . However, an up-regulation of ECE-1 mRNA could not be confirmed in rats with either mild LV dysfunction or overt heart failure (Lepailleur-Enouf et al. 2001) . Conversely, Lepailleur-Enouf et al. (2001) as well as others (Tonnessen et al. 1998) reported that increased preproendothelin mRNA levels in the lungs contribute to increased ET production in rats with MI-induced heart failure. However, in animals with mild LV dysfunction (resembling the porcine MI model in the present study) preproendothelin mRNA levels were still normal (Lepailleur-Enouf et al. 2001) , suggesting that increased preproendothelin expression might be a feature of more advanced stages of heart failure. It should be noted that in all these studies, involving protein and/or mRNA expression, total lung tissue was used. As ECE-1 as well as preproendothelin are also present in bronchial epithelial cells (Saleh et al. 1997; Takizawa et al. 1998; Ahmed et al. 2000; Yap et al. 2000) , interpretation of these studies using total lung tissue is difficult. Future studies using only pulmonary resistance vessels, are required to investigate the molecular alterations underlying an increased production of ET in more detail. The mechanisms underlying the reported increases in ECE activity and/or preproendothelin levels in pulmonary hypertension secondary to LV failure are incompletely understood, but could be caused, at least in part, by endothelial dysfunction. Thus, in patients with secondary pulmonary hypertension due to heart failure, basal pulmonary NO production is reduced (Moraes et al. 2000) . NO is capable of limiting ET-production (Lavallee et al. 2001; Alonso & Radomski, 2003; Kelly et al. 2004) , and in support of this, we recently found that loss of NO synthesis, resulted in an enhanced pulmonary vasoconstrictor influence of ET in normal swine . However, we previously failed to observe a loss of the vasodilator influence of NO in the pulmonary circulation after MI (Haitsma et al. 2002) , suggesting that at this stage of LV dysfunction, the increased plasma ET levels are not the result of loss of NO bioavailability. Future studies, investigating the effects of ET receptor antagonists following NO synthase inhibition in swine with pulmonary hypertension after MI, are required to test this hypothesis more rigorously.
ET receptor subtypes involved in pulmonary hypertension
ET-induced constriction of large pulmonary arteries is principally mediated by ET A receptors (MacLean et al. 1994; Perreault & Baribeau, 1995) , whereas constriction in the smaller pulmonary resistance vessels is mediated by ET B receptors (MacLean et al. 1994) . These findings are supported by observations that the density of ET A receptors in the lung decreases with decreasing vessel size, J Physiol 574.2 whereas the density of ET B receptors, both on the endothelium and the smooth muscle, increases (Soma et al. 1999) .
In normal swine, blockade of either ET A receptors alone or combined blockade of ET A and ET B receptors had no effect on PVR at rest, indicating that endogenous ET does not contribute to resting tone in the pulmonary resistance vessels (Merkus et al. 2003) . During exercise, however, an ET-mediated vasoconstriction became apparent that was ET B receptor-mediated with no contribution of ET A receptors (Merkus et al. 2003; Houweling et al. 2005) . This ET B -mediated vasoconstriction that limits the pulmonary vasodilatation in response to exercise (Merkus et al. 2003) , is consistent with the localization of the ET B receptors on the pulmonary resistance vessels (Soma et al. 1999) .
In swine with secondary pulmonary hypertension, the increased pulmonary vasodilator response to mixed ET A /ET B receptor blockade was increased in MI compared to normal swine. Both plasma ET levels and sensitivity of the pulmonary circulation to exogenous ET (via intravenous infusion) were increased, and probably acted in concert to increase the pulmonary vasoconstrictor influence of ET in MI swine. Although we cannot entirely exclude the possibility that other neurohormones, including noradrenaline and angiotensin II, contributed to the increased pulmonary resistance vessel tone after MI, it is important to note that mixed ET A /ET B receptor blockade abolished the differences in PVR between normal and MI swine (see Fig. 4 ). This finding is consistent with the concept that an increased ET-mediated vasoconstrictor influence was principally responsible for the increase in pulmonary resistance vessel tone after MI.
Although the ET A receptor does not contribute to the regulation of pulmonary vasomotor tone in normal swine at rest or during exercise, an ET A -mediated vasoconstriction emerged after MI. This ET A -mediated vasoconstriction appeared tonic in nature, so that it did not increase further during exercise. This increased vasoconstrictor influence of the ET A receptor may also have contributed to the increased pulmonary sensitivity to exogenous ET. This is in accordance with a study in pigs with pacing-induced heart failure, which showed that ET A receptor mRNA and ET A binding are increased (Ergul et al. 2001) . Similarly, data in dogs showed that, whereas pulmonary vasoconstriction in response to exogenous ET is predominantly mediated through the ET B receptor in normal dogs, there is an ET A -mediated component in dogs with pacing-induced heart failure (Tadano et al. 2004 ). Conversely, Docherty & MacLean (1998) investigated the effect of ET on isolated pulmonary arterioles in animals with MI using ET receptor agonists and antagonists, and found no contribution of the ET A receptor to pulmonary vasoconstriction in either normal rabbits or rabbits with MI. Similarly, several studies in rats showed no alterations in ET A mRNA and/or protein expression in the lung after MI (Kobayshi et al. 1998; Lepailleur-Enouf et al. 2001) . However, in all studies, involving protein and/or mRNA expression, total lung tissue was used. Because ET A as well as ET B receptors are also present in bronchial airway smooth muscle and lung alveoli (Goldie, 1998) , interpretation of these studies using total lung tissue is difficult.
Comparison of the vasodilator effect of ET A and ET A /ET B receptor blockade in normal and MI swine suggests that the contribution of the ET B receptor to the regulation of pulmonary vasomotor tone remained unaltered after MI. These data are in apparent contrast to the majority of studies on ET B receptor expression, both at the level of mRNA (Ivy et al. 1998; Lepailleur-Enouf et al. 2001 ) and the level of protein binding (Kobayshi et al. 1998; Ergul et al. 2001) , which indicate that ET B receptor expression as well as ET B -mediated clearance are reduced in lungs of animals with heart failure. However, in these studies, ET B receptors on the endothelial cells and on the vascular smooth muscle cells cannot be distinguished. It is therefore possible that ET B receptors on the endothelium, which are responsible for vasodilatation and clearance, are reduced to the same extent as ET B receptors on vascular smooth muscle, which induce vasoconstriction. The net effect would then be that the ET B -mediated vasoconstriction in response to endogenous ET would remain more or less constant, while clearance is reduced.
Clinical relevance
In the treatment of pulmonary hypertension, ET antagonism is a promising therapy. There have been several clinical trials that have demonstrated improvement in haemodynamic variables and exercise capacity and reduction in the number of clinical events after administration of an ET A receptor antagonist or a mixed ET A /ET B receptor antagonist (Channick et al. 2001; Rubin et al. 2002; Barst et al. 2004; Galie et al. 2005) . It has been proposed that ET A receptor blockade would be a good option because it leaves the ET B -mediated clearance of ET as well as the endothelium ET B -mediated pulmonary vasodilatation unaffected. However, comparison of clinical trials using either ET A or combined ET A /ET B receptor antagonists (Motte et al. 2005) , suggests that exercise capacity of patients with pulmonary hypertension improves more with combined ET A /ET B than with ET A receptor antagonists. The observations in the present study in MI swine provide further support for the use of combined ET A /ET B receptor antagonism in patients with secondary pulmonary hypertension. This important issue is currently being investigated in the prospective STRIDE-2 clinical trial, comparing treatment with ET A receptor antagonism versus combined ET A /ET B receptor antagonism Cleland et al. 2005) .
